EIF4A3 and liver cancer: To further validate this idea and to explore the putative utility of blocking EIF4A3 and FGFR4 simultaneously in liver cancer cells, we performed functional assays in response to EIF4A3‐silencing alone or in combination with a specific FGFR4‐inhibitor (BLU9931 or BLU).